Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 10:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Actonel Clear all
Completed No phase listed Observational

Replication of the VERO Osteoporosis Trial in Healthcare Claims Data

NCT04879420
View directory record Official record
Conditions
Osteoporosis
Interventions
Teriparatide, Risedronate
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
45 Years to 120 Years · Female only
Enrollment
12,757 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 11, 2026, 10:39 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose

NCT00577850
View directory record Official record
Conditions
Osteopenia, Osteoporosis
Interventions
risedronate, alendronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
2
States / cities
Gainesville, Florida • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Sep 11, 2026, 10:39 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarker Identification in Orthopaedic & Oral Maxillofacial Surgery Subjects to Identify Risks of Bisphosphonate Use

NCT01875458
View directory record Official record
Conditions
Osteoporosis, With or Without Treatment, Bisphosphonate Treatment, Atypical Femur Fracture, Bisphosphonate Related Osteonecrosis of the Jaws (BRONJ), Healthy Volunteers
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Sep 11, 2026, 10:39 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Assess the Safety, Efficacy, and Pharmacokinetics of Immediate and Delayed Release Weekly Risedronate

NCT00577720
View directory record Official record
Conditions
Postmenopausal Women
Interventions
risedronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
45 Years to 80 Years · Female only
Enrollment
181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
6
States / cities
Costa Mesa, California • Gainsville, Florida • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2012 · Synced Sep 11, 2026, 10:39 AM EDT
Completed Phase 4 Interventional

OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal Women

NCT00130403
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
risedronate sodium
Drug
Lead sponsor
Sanofi
Industry
Eligibility
55 Years to 85 Years · Female only
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Sep 11, 2026, 10:39 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Bone Loss in Women With Anorexia Nervosa

NCT00089843
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Testosterone, Actonel (risedronate), Placebo Actonel (risedronate), Placebo testosterone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Sep 11, 2026, 10:39 AM EDT
Completed No phase listed Observational

Analysis of Iliac Crest Biopsies From Patients Receiving Risedronate

NCT00837746
View directory record Official record
Conditions
Osteoporosis
Interventions
risedronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
7
States / cities
Palm Desert, California • Lakewood, Colorado • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Sep 11, 2026, 10:39 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children

NCT00106028
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
risedronate sodium (Actonel), Placebo
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
4 Years to 15 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
5
States / cities
Miami, Florida • Omaha, Nebraska • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2013 · Synced Sep 11, 2026, 10:39 AM EDT
Terminated Phase 3 Interventional Results available

Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy

NCT00216060
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
Risedronate, Placebo
Drug
Lead sponsor
Christopher Sweeney, MBBS
Other
Eligibility
18 Years and older · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
31
States / cities
La Mesa, California • San Bernardino, California • New Britain, Connecticut + 26 more
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Sep 11, 2026, 10:39 AM EDT
Completed Not applicable Interventional Results available

IGF-1 and Bone Loss in Women With Anorexia Nervosa

NCT01406444
View directory record Official record
Conditions
Anorexia Nervosa, Osteopenia, Osteoporosis
Interventions
rhIGF-1, Risedronate, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Sep 11, 2026, 10:39 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Weight Loss With Risedronate for Bone Health

NCT03411902
View directory record Official record
Conditions
Bariatric Surgery Candidate, Bone Loss, Weight Loss
Interventions
Risedronate Sodium 150 MG, Placebo
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Sep 11, 2026, 10:39 AM EDT
Completed Phase 3 Interventional

Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer

NCT00054418
View directory record Official record
Conditions
Breast Cancer, Osteoporosis
Interventions
calcium carbonate, vitamin D, risedronate sodium, placebo
Dietary Supplement · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
198
States / cities
Mobile, Alabama • Scottsdale, Arizona • Aurora, Colorado + 124 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Sep 11, 2026, 10:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effects on the Relative Bioavailability of Different Dosages of Risedronate

NCT00717145
View directory record Official record
Conditions
Postmenopausal, Non-lactating, Surgically Sterile
Interventions
risedronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
3
States / cities
Gainesville, Florida • Miramar, Florida • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2011 · Synced Sep 11, 2026, 10:39 AM EDT
Completed Phase 2 Interventional

Safety, Pharmacokinetics, and Efficacy of 100, 150, and 200 mg Risedronate Administered to Women With Low BMD

NCT00577837
View directory record Official record
Conditions
Postmenopausal
Interventions
risedronate, experimental
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
50 Years to 85 Years · Female only
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
4
States / cities
Daytona Beach, Florida • Gainesville, Florida • Shawnee Mission, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Sep 11, 2026, 10:39 AM EDT
Completed Phase 4 Interventional Results available

Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use

NCT00221299
View directory record Official record
Conditions
Osteoporosis
Interventions
Risedronate, Parathyroid Hormone
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Sep 11, 2026, 10:39 AM EDT
Completed Phase 4 Interventional Results available

Antiepileptic Drugs and Osteoporotic Prevention Trial

NCT00869622
View directory record Official record
Conditions
Epilepsy, Bone Loss, Osteoporosis, Fractures
Interventions
Risedronate, Placebo + Calcium and Vitamin D
Drug
Lead sponsor
Boston VA Research Institute, Inc.
Other
Eligibility
18 Years to 85 Years · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 23, 2015 · Synced Sep 11, 2026, 10:39 AM EDT
Recruiting Phase 3 Interventional

Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery

NCT04922333
View directory record Official record
Conditions
Bone Loss
Interventions
Risedronate, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
30 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 11, 2026, 10:39 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period

NCT00051636
View directory record Official record
Conditions
Paget's Disease of Bone
Interventions
Zoledronic Acid, Risedronate, Placebo to Risedronate, Placebo to Zoledronic Acid, Calcium and Vitamin D
Drug · Dietary Supplement
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
12
States / cities
Santa Monica, California • Lakewood, Colorado • Boca Raton, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 14, 2012 · Synced Sep 11, 2026, 10:39 AM EDT
Completed Phase 3 Interventional Results available

A Study of Monthly Risedronate for Osteoporosis

NCT00247273
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
risedronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
50 Years and older · Female only
Enrollment
1,294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
7
States / cities
Lakewood, Colorado • Gainesville, Georgia • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2013 · Synced Sep 11, 2026, 10:39 AM EDT
Completed Phase 3 Interventional

Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women

NCT00358176
View directory record Official record
Conditions
Osteoporosis Postmenopausal
Interventions
Risedronate (HMR4003)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older · Female only
Enrollment
1,231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 14, 2009 · Synced Sep 11, 2026, 10:39 AM EDT
Completed Phase 3 Interventional Results available

Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis

NCT01611571
View directory record Official record
Conditions
Osteoporosis
Interventions
Risedronate, Teriparatide, Placebo Teriparatide, placebo Risedronate
Drug
Lead sponsor
Columbia University
Other
Eligibility
30 Years to 85 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2014 · Synced Sep 11, 2026, 10:39 AM EDT
Completed Phase 4 Interventional Results available

A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture

NCT00887354
View directory record Official record
Conditions
Osteoporosis
Interventions
Teriparatide, Risedronate, Placebo, Calcium, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
6
States / cities
Fort Lauderdale, Florida • New Port Richey, Florida • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 11, 2026, 10:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of Different Formulations of Risedronate in Healthy Male and Female Subjects

NCT00846196
View directory record Official record
Conditions
Osteoporosis
Interventions
risedronate DR (Phase III clinical supply), risedronate 35 mg DR (Commercial Tablet)
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years to 65 Years
Enrollment
538 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
6
States / cities
San Diego, California • Fort Myers, Florida • Miramar, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2011 · Synced Sep 11, 2026, 10:39 AM EDT
Completed Phase 3 Interventional Results available

A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis

NCT00541658
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
risedronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
50 Years and older · Female only
Enrollment
923 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
20
States / cities
Birmingham, Alabama • Oakland, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2013 · Synced Sep 11, 2026, 10:39 AM EDT